Type 1 Diabetes Trial, Recruiting NCT07360080 Sponsor: Sanofi Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Type 1 Diabetes Trial, Recruiting

NCT07360080
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must have received at least one teplizumab infusion in the 6 weeks before joining the study.
  • You must have been officially diagnosed with Stage 2 type 1 diabetes by your doctor at the time of your first teplizumab infusion (note: if your condition has since progressed to Stage 3 by week 6, you may still be eligible — confirm with trial site).
  • You (or your parent/legal guardian, if applicable) must be willing and able to sign a consent form agreeing to take part in the study.

Who may not be able to join:

  • You have taken part in a previous clinical trial specifically testing teplizumab.
  • You have been enrolled in any other clinical trial within the past 6 months (note: participation in observational studies, where no treatment is being tested, may still be allowed — confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 800-633-1610

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
19 March 2026
Est. completion
29 October 2035

Where this trial is recruiting

🇮🇱 Israel 🇦🇪 United Arab Emirates 🇺🇸 United States

Primary endpoints

Time from teplizumab infusion start to the onset of Stage 3 T1D

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov